Table 3.
Multivariate analysis of clinical factors affecting overall survival and relapse
| Overall Survival | Relapse | |||
|---|---|---|---|---|
| Variables | HR (range) | p-value | HR (range) | p-value |
| In vivo T cell depletion | ||||
| Anti-thymocyte globulin* | 1.00 | 0.023 | 1.00 | 0.001 |
| Alemtuzumab | 1.46 (1.0–2.13) | 0.049 | 1.10 (0.71–1.70) | 0.66 |
| No in vivo depletion | 0.89 (0.7–1.14) | 0.362 | 0.57 (0.4–0.81) | 0.0014 |
| Conditioning regimen | ||||
| Myeloablative* | 1.00 | 0.049 | NS | NS |
| RIC | 0.76 (0.57–1.0) | 0.05 | ||
| NMA | 0.70 (0.52–0.94) | 0.02 | ||
| Disease status | ||||
| CR/PR/nPR* | 1.0 | 1.0 | ||
| no CR/PR/nPR | 1.49.(1.14–7.56) | 0.0035 | 1.66 (1.13–2.45) | 0.010 |
| Donor type | ||||
| 8/8 HLA matched URD* | 1.0 | NS | NS | |
| 7/8 HLA matched URD | 1.56 (1.22–2.01) | 0.0004 | ||
| GVHD prophylaxis | ||||
| Tac+−others* | 1.00 | 0.0130 | NS | NS |
| Tac+ MTX or MMF+− other(s) | 0.64 (0.49–0.85) | 0.0016 | ||
| CSA +/−others | 0.80 (0.61–1.05) | 0.1117 | ||
| Karnofsky score | ||||
| <80%* | 1.0 | 1.0 | ||
| 80–100% | 0.46 (0.32–0.66) | 0.0001 | 0.42 (0.26–0.69) | 0.0005 |
| Number of chemotherapy line | ||||
| 3* | 1.0 | 1.0 | ||
| >3 | 2.54 (1.64–3.94) | 0.0001 | 1.82 (0.99–3.34) | 0.053 |
*
reference category, Abbreviations: OS overall survival, GVHD graft-versus-host disease, ATG, antithymocyte globulin; CSA, cyclosporin A; CR, complete response; NS, not significant, not included in multivariate model for outcome; nPR, nodal partial response; PR, partial response; MMF, mycophenolate mofetil; MTX, methotrexate; Tac, tacrolimus, RIC reduced intensity regimen, NMA, non-myeloablative.